Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults
- PMID: 25483452
- PMCID: PMC4355212
- DOI: 10.3322/caac.21258
Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults
Abstract
Answer questions and earn CME/CNE Over the past few decades, a body of research has emerged confirming what many adult patients with noncentral nervous system cancer have long reported-that cancer and its treatment are frequently associated with cancer-related cognitive impairment (CRCI). The severity of CRCI varies, and symptoms can emerge early or late in the disease course. Nonetheless, CRCI is typically mild to moderate in nature and primarily involves the domains of memory, attention, executive functioning, and processing speed. Animal models and novel neuroimaging techniques have begun to unravel the pathophysiologic mechanisms underlying CRCI, including the role of inflammatory cascades, direct neurotoxic effects, damage to progenitor cells, white matter abnormalities, and reduced functional connectivity, among others. Given the paucity of research on CRCI with other cancer populations, this review synthesizes the current literature with a deliberate focus on CRCI within the context of breast cancer. A hypothetical case-study approach is used to illustrate how CRCI often presents clinically and how current science can inform practice. While the literature regarding intervention for CRCI is nascent, behavioral and pharmacologic approaches are discussed.
Keywords: breast neoplasms; chemotherapy; complications and late effects of therapy; psychological/behavioral oncology.
© 2014 American Cancer Society.
Conflict of interest statement
The remaining authors report no conflicts of interest.
Similar articles
-
[Chemotherapy-related Cognitive Impairment in Patients with Hodgkin Lymphoma - Pathophysiology and Risk Factors].Klin Onkol. 2017 Spring;30(2):93-99. doi: 10.14735/amko201793. Klin Onkol. 2017. PMID: 28397504 Review. Czech.
-
Chemotherapy-related cognitive impairment in older patients with cancer.J Geriatr Oncol. 2016 Jul;7(4):270-80. doi: 10.1016/j.jgo.2016.04.008. Epub 2016 Jul 5. J Geriatr Oncol. 2016. PMID: 27197918 Free PMC article. Review.
-
Cognitive Changes Related to Cancer Therapy.Med Clin North Am. 2017 Nov;101(6):1115-1134. doi: 10.1016/j.mcna.2017.06.006. Epub 2017 Aug 25. Med Clin North Am. 2017. PMID: 28992858 Review.
-
Breast cancer plus adjuvant chemotherapy- related cognitive impairment: a case study.Neurocase. 2019 Jun-Aug;25(3-4):138-144. doi: 10.1080/13554794.2019.1627374. Epub 2019 Jun 25. Neurocase. 2019. PMID: 31237172
-
Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors.Ann Oncol. 2019 Dec 1;30(12):1925-1940. doi: 10.1093/annonc/mdz410. Ann Oncol. 2019. PMID: 31617564 Free PMC article. Review.
Cited by
-
Altered gyrification in chemotherapy-treated older long-term breast cancer survivors.Brain Behav. 2024 Aug;14(8):e3634. doi: 10.1002/brb3.3634. Brain Behav. 2024. PMID: 39169605 Free PMC article.
-
Cognition in patients treated with targeted therapy for chronic myeloid leukemia: a controlled comparison.Leuk Lymphoma. 2023 Feb;64(2):415-423. doi: 10.1080/10428194.2022.2148208. Epub 2022 Dec 7. Leuk Lymphoma. 2023. PMID: 36476293 Free PMC article.
-
The Fast Cognitive Evaluation (FaCE): a screening tool to detect cognitive impairment in patients with cancer.BMC Cancer. 2023 Jan 9;23(1):35. doi: 10.1186/s12885-022-10470-1. BMC Cancer. 2023. PMID: 36624397 Free PMC article.
-
CanCOG®: Cultural Adaptation of the Evidence-Based UCLA Cognitive Rehabilitation Intervention Program for Cancer Survivors in Portugal.Healthcare (Basel). 2023 Jan 2;11(1):141. doi: 10.3390/healthcare11010141. Healthcare (Basel). 2023. PMID: 36611601 Free PMC article.
-
Type of cancer treatment and cognitive symptoms in working cancer survivors: an 18-month follow-up study.J Cancer Surviv. 2020 Apr;14(2):158-167. doi: 10.1007/s11764-019-00839-w. Epub 2020 Jan 15. J Cancer Surviv. 2020. PMID: 31940106 Free PMC article.
References
-
- Nelson WL, Suls J. New approaches to understand cognitive changes associated with chemotherapy for non-central nervous system tumors. J Pain Symptom Manage. 2013;46:707–721. - PubMed
-
- Weiss HD, Walker MD, Wiernik PH. Neurotoxicity of commonly used antineoplastic agents (first of two parts) N Engl J Med. 1974;291:75–81. - PubMed
-
- Ouimet LA, Stewart A, Collins B, Schindler D, Bielajew C. Measuring neuropsychological change following breast cancer treatment: an analysis of statistical models. J Clin Exp Neuropsychol. 2009;31:73–89. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous